Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer

Cancer Letters

Volumn 351, Issue 1, 2014, Pages 6-12

  Zhang, Jingze ^a   Yu, Jinming ^a   Sun, Xindong ^a   Meng, Xue ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Brain metastasis; EGFR TKI; NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

BLOOD BRAIN BARRIER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EFFECTIVENESS; DIARRHEA; DOSE RESPONSE; DOSIMETRY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRANSAMINASEMIA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RASH; SHORT SURVEY; SKIN DISEASE; SOMNOLENCE;

BRAIN METASTASIS; EGFR TKI; NSCLC;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84903723265     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.04.019     Document Type: Review

References (65)

1. Mujoomdar A., Austin J.H., Malhotra R., Powell C.A., Pearson G.D., Shiau M.C., et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007, 242(3):882-888. 10.1148/radiol.2423051707.
2. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J. Clin. Oncol. 2004, 22(14):2865-2872. 10.1200/JCO.2004.12.149.
3. Nussbaum E.S., Djalilian H.R., Cho K.H., Hall W.A. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996, 78(8):1781-1788.
4. Priestman T.J., Dunn J., Brada M., Rampling R., Baker P.G. Final results of the Royal College of Radiologists trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin. Oncol. (R. Coll. Radiol.) 1996, 8(5):308-315.
5. Andrews D.W., Scott C.B., Sperduto P.W., Flanders A.E., Gaspar L.E., Schell M.C., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363(9422):1665-1672. 10.1016/S0140-6736(04)16250-8.
6. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., Padberg G.W., Voormolen J.H., Hoekstra F.H., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann. neurol. 1993, 33(6):583-590. 10.1002/ana.410330605.
7. Moscetti L., Nelli F., Felici A., Rinaldi M., De Santis S., D'Auria G., et al. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by outcome research network for evaluation of treatment results in oncology. Cancer 2007, 109(2):274-281. 10.1002/cncr.2239.
8. Postmus P.E., Smit E.F. Chemotherapy for brain metastases of lung cancer: a review. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO. 1999, 10(7):753-759.
9. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350(21):2129-2139. 10.1056/NEJMoa040938.
10. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 2011, 29(21):2866-2874. 10.1200/JCO.2010.33.4235.
11. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12(8):735-742. 10.1016/S1470-2045(11)70184-X.
12. Porta R., Sanchez-Torres J.M., Paz-Ares L., Massuti B., Reguart N., Mayo C., et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur. Respir. J. 2011, 37(3):624-631. 10.1183/09031936.00195609.
13. Park S.J., Kim H.T., Lee D.H., Kim K.P., Kim S.W., Suh C., et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Canc. (Amsterdam, Netherlands). 2012, 77(3):556-560. 10.1016/j.lungcan.2012.05.09.
14. Shapiro W.R., Shapiro J.R. Principles of brain tumor chemotherapy. Semin. Oncol. 1986, 13(1):56-69.
15. Greig N.H., Soncrant T.T., Shetty H.U., Momma S., Smith Q.R., Rapoport S.I. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother. Pharmacol. 1990, 26(4):263-268.
16. Eichler A.F., Chung E., Kodack D.P., Loeffler J.S., Fukumura D., Jain R.K. The biology of brain metastases-translation to new therapies. Nat. Rev. Clin. Oncol. 2011, 8(6):344-356. 10.1038/nrclinonc.2011.58.
17. Weber B., Winterdahl M., Memon A., Sorensen B.S., Keiding S., Sorensen L., et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Canc. 2011, 6(7):1287-1289. 10.1097/JTO.0b013e318219ab87.
18. Laquintana V., Trapani A., Denora N., Wang F., Gallo J.M., Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin. Drug Del. 2009, 6(10):1017-1032. 10.1517/17425240903167942.
19. Togashi Y., Masago K., Masuda S., Mizuno T., Fukudo M., Ikemi Y., et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother. Pharmacol. 2012, 70(3):399-405. 10.1007/s00280-012-1929-4.
20. Zhao J., Chen M., Zhong W., Zhang L., Li L., Xiao Y., et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin. Lung Canc. 2013, 14(2):188-193. 10.1016/j.cllc.2012.06.004.
21. Togashi Y., Masago K., Fukudo M., Terada T., Fujita S., Irisa K., et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Canc. 2010, 5(7):950-955. 10.1097/JTO.0b013e3181e2138b.
22. Masuda T., Hattori N., Hamada A., Iwamoto H., Ohshimo S., Kanehara M., et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother. Pharmacol. 2011, 67(6):1465-1469. 10.1007/s00280-011-1555-6.
23. Chen Y., Wang M., Zhong W., Zhao J. Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. Lung Canc. (Amsterdam, Netherlands). 2013, 10.1016/j.lungcan.2013.08.01.
24. Lassman A.B., Rossi M.R., Raizer J.J., Abrey L.E., Lieberman F.S., Grefe C.N., et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Canc. Res.: Off. J. Am. Assoc. Canc. Res. 2005, 11(21):7841-7850. 10.1158/1078-0432.ccr-05-0421.
25. Grommes C., Oxnard G.R., Kris M.G., Miller V.A., Pao W., Holodny A.I., et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology 2011, 13(12):1364-1369. 10.1093/neuonc/nor121.
26. Jackman D.M., Holmes A.J., Lindeman N., Wen P.Y., Kesari S., Borras A.M., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J. Clin. Oncol. 2006, 24(27):4517-4520. 10.1200/JCO.2006.06.6126.
27. Clarke J.L., Pao W., Wu N., Miller V.A., Lassman A.B. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J. Neurooncol. 2010, 99(2):283-286. 10.1007/s11060-010-0128-6.
28. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 2010, 28(2):357-360. 10.1200/JCO.2009.24.7049.
29. Dhruva N., Socinski M.A. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J. Clin. Oncol. 2009, 27(22):e31-e32. 10.1200/JCO.2008.21.0963.
30. Togashi Y., Masago K., Fukudo M., Tsuchido Y., Okuda C., Kim Y.H., et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother. Pharmacol. 2011, 68(4):1089-1092. 10.1007/s00280-011-1691-z.
31. Hata A., Kaji R., Fujita S., Katakami N. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Canc. 2011, 6(3):653-654. 10.1097/JTO.0b013e3181d899bb.
32. Milton D.T., Azzoli C.G., Heelan R.T., Venkatraman E., Gomez J.E., Kris M.G., et al. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 2006, 107(5):1034-1041. 10.1002/cncr.22088.
33. Katayama T., Shimizu J., Suda K., Onozato R., Fukui T., Ito S., et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Canc. 2009, 4(11):1415-1419. 10.1097/JTO.0b013e3181b62572.
34. Chinnaiyan P., Huang S., Vallabhaneni G., Armstrong E., Varambally S., Tomlins S.A., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005, 65(8):3328-3335. 10.1158/0008-5472.CAN-04-3547.
35. Bianco C., Tortora G., Bianco R., Caputo R., Veneziani B.M., Caputo R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Canc. Res.: Off. J. Am. Assoc. Canc. Res. 2002, 8(10):3250-3258.
36. Huang S.M., Li J., Armstrong E.A., Harari P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 2002, 62(15):4300-4306.
37. d'Avella D., Cicciarello R., Albiero F., Mesiti M., Gagliardi M.E., Russi E., et al. Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation. Neurosurgery 1992, 30(1):30-34.
38. d'Avella D., Cicciarello R., Angileri F.F., Lucerna S., La Torre D., Tomasello F. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir. Suppl. 1998, 71:282-284.
39. D. Qin, R. Zheng, J. Ma, J. Xiao, Z. Tang, Influence of radiation on the blood-brain barrier and optimum time of chemotherapy, Zhongguo Yi, Xue Ke, Xue Yuan, Xue Bao, 21 (4) (1999) 307-310.
40. Qin D., Ma J., Xiao J., Tang Z. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am. J. Clin. Oncol. 1997, 20(3):263-265.
41. Qin D., Ou G., Mo H., Song Y., Kang G., Hu Y., et al. Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51(4):959-962.
42. DeAngelis L.M., Delattre J.Y., Posner J.B. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989, 39(6):789-796.
43. Lind J.S., Lagerwaard F.J., Smit E.F., Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74(5):1391-1396. 10.1016/j.ijrobp.2008.10.026.
44. Ma S., Xu Y., Deng Q., Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Canc. (Amsterdam, Netherlands) 2009, 65(2):198-203. 10.1016/j.lungcan.2008.10.02.
45. Welsh J.W., Komaki R., Amini A., Munsell M.F., Unger W., Allen P.K., et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J. Clin. Oncol. 2013, 31(7):895-902. 10.1200/JCO.2011.40.1174.
46. Lagerwaard F.J., Levendag P.C., Nowak P.J., Eijkenboom W.M., Hanssens P.E., Schmitz P.I. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int. J. Radiat. Oncol. Biol. Phys. 1999, 43(4):795-803.
47. Ceresoli G.L., Cappuzzo F., Gregorc V., Bartolini S., Crino L., Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO. 2004, 15(7):1042-1047. 10.1093/annonc/mdh276.
48. Zeng Y.D., Zhang L., Liao H., Liang Y., Xu F., Liu J.L., et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac. J. Cancer Prev. 2012, 13(3):909-914.
49. Sperduto P.W., Wang M., Robins H.I., Schell M.C., Werner-Wasik M., Komaki R., et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiation therapy oncology group 0320. Int. J. Radiat. Oncol. Biol. Phys. 2013, 85(5):1312-1318. 10.1016/j.ijrobp.2012.11.042.
50. Zhuang H., Yuan Z., Wang J., Zhao L., Pang Q., Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des. Dev. Ther. 2013, 7:1179-1186. 10.2147/dddt.s53011.
51. Benavente S., Huang S., Armstrong E.A., Chi A., Hsu K.T., Wheeler D.L., et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin. Canc. Res.: Off. J. Am. Assoc. Canc. Res. 2009, 15(5):1585-1592. 10.1158/1078-0432.CCR-08-2068.
52. Hirata H., Nakamura K., Kunitake N., Shioyama Y., Sasaki T., Ohga S., et al. Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma. Anticancer Res. 2013, 33(4):1649-1655.
53. Shukuya T., Takahashi T., Naito T., Kaira R., Ono A., Nakamura Y., et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Canc (Amsterdam, Netherlands). 2011, 74(3):457-461. 10.1016/j.lungcan.2011.04.00.
54. Wu C., Li Y.L., Wang Z.M., Li Z., Zhang T.X., Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Canc (Amsterdam, Netherlands). 2007, 57(3):359-364. 10.1016/j.lungcan.2007.03.01.
55. Hotta K., Kiura K., Ueoka H., Tabata M., Fujiwara K., Kozuki T., et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Canc (Amsterdam, Netherlands) 2004, 46(2):255-261. 10.1016/j.lungcan.2004.04.03.
56. Namba Y., Kijima T., Yokota S., Niinaka M., Kawamura S., Iwasaki T., et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin. Lung Canc. 2004, 6(2):123-128. 10.3816/CLC.2004.n.026.
57. Chiu C.H., Tsai C.M., Chen Y.M., Chiang S.C., Liou J.L., Perng R.P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Canc (Amsterdam, Netherlands). 2005, 47(1):129-138. 10.1016/j.lungcan.2004.05.01.
58. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY). 2004, 304(5676):1497-1500. 10.1126/science.109931.
59. Matsumoto S., Takahashi K., Iwakawa R., Matsuno Y., Nakanishi Y., Kohno T., et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int. J. Canc. J. Int. Canc. 2006, 119(6):1491-1494. 10.1002/ijc.21940.
60. Daniele L., Cassoni P., Bacillo E., Cappia S., Righi L., Volante M., et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Canc. 2009, 4(6):684-688. 10.1097/JTO.0b013e3181a52359.
61. Benedettini E., Sholl L.M., Peyton M., Reilly J., Ware C., Davis L., et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. The Am. J. Pathol. 2010, 177(1):415-423. 10.2353/ajpath.2010.090863.
62. Cassoni P., Daniele L., Maldi E., Righi L., Tavaglione V., Novello S., et al. Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology 2009, 55(1):20-27. 10.1111/j.1365-2559.2009.03326.x.
63. Iuchi T., Shingyoji M., Sakaida T., Hatano K., Nagano O., Itakura M., et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Canc (Amsterdam, Netherlands). 2013, 10.1016/j.lungcan.2013.08.01.
64. Li Z., Lu J., Zhao Y., Guo H. The retrospective analysis of the frequency of EGFR mutations and efficacy of gefitinib in NSCLC patients with brain metastases. J. Clin. Oncol. 2011, 29. e18065.
65. Heon S., Yeap B., Lindeman N., Rabin M., Jackman D., Johnson B. Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy. J. Clin. Oncol. 2011, 29:7607.